Pembrolizumab plus Lenvatinib
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Angiosarcoma of Skin
Conditions
Angiosarcoma of Skin, Angiosarcoma Metastatic
Trial Timeline
Dec 1, 2024 → Nov 30, 2029
NCT ID
NCT06673628About Pembrolizumab plus Lenvatinib
Pembrolizumab plus Lenvatinib is a phase 2 stage product being developed by Merck for Angiosarcoma of Skin. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06673628. Target conditions include Angiosarcoma of Skin, Angiosarcoma Metastatic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06673628 | Phase 2 | Recruiting |
Competing Products
6 competing products in Angiosarcoma of Skin
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eribulin | Eisai | Phase 2 | 52 |
| Avelumab + Paclitaxel | Merck | Phase 2 | 52 |
| Pazopanib + Paclitaxel | Novartis | Phase 2 | 52 |
| regorafenib | Bayer | Phase 2 | 49 |
| Vusolimogene Oderparepvec (VO) + Pembrolizumab | Replimune | Phase 2 | 44 |
| AGEN2034 + AGEN1884 | Agenus | Phase 2 | 44 |